In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2010-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00280-009-1113-7PMID 19727731PMCID PMC8450814
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• -deoxyguanosine and Bcnu ′ -benzyl-2 6 O Treatment of Human Brain Tumor Xenografts with Updated Version Citing Articles E-mail Alerts Treatment of Human Brain Tumor Xenografts with 06-benzyl-2'-deoxyguanosine and Bcnu1

  2013cited by this paper
• alpha Isoforms of soluble and membrane-linked folate-binding protein in human blood.

  2008cited by this paper
• Phase 1 trial of O6‐benzylguanine and BCNU in children with CNS tumors: A Children's Oncology Group study

  2008cited by this paper
• Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase.

  2008cited by this paper
• Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine.

  2007cited by this paper
• Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

  2006cited by this paper
• Treatment of subcutaneous and intracranial brain tumor xenografts withO6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea

  2004cited by this paper
• Effect ofO6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer

  2004cited by this paper
• Relevance of clonogenic assays in hematotoxicology

  2004cited by this paper
• 2-amino-O4-benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase.

  2004cited by this paper
• Bioditribution ofO6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL

  2004cited by this paper
• In vitro bone marrow granulocyte-macrophage progenitor cultures in the assessment of hematotoxic potential of the new drugs

  2004cited by this paper
• Differential toxicity of anticancer drugs on late (GM-CFC) and early (LTC-IC) hemopoietic progenitors in vitro

  2004cited by this paper
• Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy.

  2004cited by this paper
• Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine

  2004cited by this paper
• Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.

  2003cited by this paper
• Myeloid clonogenic assays for comparison of the in vitro toxicity of alkylating agents.

  2003cited by this paper
• Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.

  2003cited by this paper
• Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.

  2002influential reference
• O6-benzylguanine-mediated enhancement of chemotherapy.

  2002cited by this paper
• Inactivation of human O(6)-alkylguanine-DNA alkyltransferase by modified oligodeoxyribonucleotides containing O(6)-benzylguanine.

  2001cited by this paper
• Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay.

  2001cited by this paper
• Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

  2000cited by this paper
• Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

  2000cited by this paper
• O6-Benzylguanine-mediated enhancement of nitrosourea activity in Mer− central nervous system tumor xenografts – implications for clinical trials

  2000cited by this paper
• Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells.

  1999influential reference
• Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

  1998cited by this paper
• Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests.

  1998cited by this paper
• Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.

  1997cited by this paper
• Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro

  1997cited by this paper
• Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea.

  1995cited by this paper
• Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.

  1995cited by this paper
• In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow.

  1994cited by this paper
• Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications

  1994cited by this paper
• Enhancement by O6-benzyl-N-acetylguanosine derivatives of chloroethylnitrosourea antitumor action in chloroethylnitrosourea-resistant human malignant melanocytes.

  1994cited by this paper
• Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).

  1993cited by this paper
• Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning

  1993cited by this paper
• Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.

  1992cited by this paper
• Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.

  1992cited by this paper
• Enhancement of Nitrosourea Activity in Medulloblastoma and Glioblastoma Multiforme

  1992cited by this paper
• Utility of human bone marrow obtained incidental to orthopedic surgery for hematopoietic clonal assays.

  1991cited by this paper
• Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.

  1990cited by this paper
• Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro.

  1990cited by this paper
• DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal.

  1990cited by this paper
• In vitro myelotoxicity of 2',3'-dideoxynucleosides on human hematopoietic progenitor cells.

  1990cited by this paper
• Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea.

  1987cited by this paper
• Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base.

  1986cited by this paper
• Contributions of nitrosoureas to cancer treatment.

  1986cited by this paper
• Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents.

  1986cited by this paper
• Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems.

  1986cited by this paper
• Contributions of nitrosoureas to cancer treatment.

  1986cited by this paper
• Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems.

  1986cited by this paper
• Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines.

  1985cited by this paper
• Exposure of HeLa cells to 0(6)-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents.

  1985cited by this paper
• Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts.

  1984cited by this paper

• Understanding the Correlation between in vitro and in vivo Immunotoxicity Tests for Engineered Nanomaterials

  2016cites this paper
• Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.

  2013cites this paper
• Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model

  2011cites this paper